- Dr Senthil Sockalingham,

Chief Medical Officer and Head, IQVIA Biotech Asia Pacific, Singapore

“COVID-19 has catalysed decentralised clinical trials (DCT) and they will increasingly become the norm. Alongside this is the increased adoption of big data, artificial intelligence (AI), and machine learning (ML), including identifying potential drug candidates.”